FAAP24: A Potential Drug Target and Biomarker for Fanconi Anemia

Target Name: FAAP24

NCBI ID: G91442

FAAP24

FAAP24: A Potential Drug Target and Biomarker for Fanconi Anemia

Abstract:

Fanconi anemia is a rare genetic disorder that affects the production of functional red blood cells, leading to anemia, fatigue, and other serious health complications. The FAAP24 gene, located on chromosome 15, has been identified as a potential drug target and biomarker for this disorder. This article will summarize the research on FAAP24 and its potential as a drug target and biomarker for Fanconi anemia.

Introduction:

Fanconi anemia is a genetic disorder that affects the production of functional red blood cells, leading to anemia, fatigue, and other serious health complications. The severity of the disorder varies from one case to another, but the characteristic symptoms remain consistent. The most common form of the disorder is the severe anemia, which is caused by a deficiency of the protein hemoglobin. In severe anemia, the anemia can be life-threatening, and there is no effective treatment available to reverse the anemia.

The FAAP24 gene:

The FAAP24 gene, located on chromosome 15, is a gene that encodes a protein called FAAP24. The protein produced by the FAAP24 gene is a member of the Fanconi anemia core complex-associated protein (FAAP) family. The FAAP24 protein is a key component of the FAAP24 complex, which is responsible for the production of functional red blood cells.

The FAAP24 protein:

The FAAP24 protein is a 24-kDa protein that plays a critical role in the production of functional red blood cells. It is a key component of the FAAP24 complex, which consists of four other proteins: FAAP21, FAAP22, FAAP23, and FAAP24. The FAAP24 protein is responsible for interacting with the other proteins in the complex and for helping them to function properly.

The potential drug target:

The FAAP24 protein is a potential drug target for Fanconi anemia because of its role in the production of functional red blood cells. Drugs that can inhibit the activity of the FAAP24 protein or its interactions with other proteins in the FAAP24 complex could potentially be used to treat Fanconi anemia.

The potential biomarker:

The FAAP24 protein may also be used as a biomarker for Fanconi anemia. The severity of the disorder is often determined by the level of the protein in the blood. Therefore, measuring the level of the FAAP24 protein in the blood could be an effective way to diagnose Fanconi anemia.

Conclusion:

In conclusion, the FAAP24 gene has been identified as a potential drug target and biomarker for Fanconi anemia. The research on FAAP24 is still in its early stages, but the potential of this protein as a drug target and biomarker for Fanconi anemia is promising. Further studies are needed to fully understand the role of FAAP24 in the treatment and diagnosis of Fanconi anemia.

Protein Name: FA Core Complex Associated Protein 24

Functions: Plays a role in DNA repair through recruitment of the FA core complex to damaged DNA. Regulates FANCD2 monoubiquitination upon DNA damage. Induces chromosomal instability as well as hypersensitivity to DNA cross-linking agents, when repressed. Targets FANCM/FAAP24 complex to the DNA, preferentially to single strand DNA

The "FAAP24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAAP24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets